Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00010114

Enrollment

Registered

2003-06-06

Start date

2001-03-31

Completion date

2003-03-31

Last updated

2011-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Nervous System Embryonal Neoplasm

Keywords

childhood central nervous system germ cell tumor, childhood choroid plexus tumor, untreated childhood supratentorial primitive neuroectodermal tumor, untreated childhood medulloblastoma, newly diagnosed childhood ependymoma

Brief summary

RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to learn more about genes involved in the development of central nervous system tumors in young children.

Detailed description

OBJECTIVES: * Identify known genes that have significantly different levels of expression, using microarray gene chip analysis, in infants with newly diagnosed metastatic vs non-metastatic embryonal central nervous system tumors. * Determine the protein expression of genes identified by microarray analysis that are involved in cellular functions that regulate angiogenesis, invasion, or metastasis in this patient population. * Determine the quantity of gene expression of the confirmed translationally expressed genes using semi-quantitative polymerase chain reaction. OUTLINE: This is a multicenter study. Tumor samples are analyzed using microarray gene chip analysis. Differentially expressed genes are evaluated for protein expression by standard immunohistochemistry and/or Western blot analysis, and gene expression is further quantified by semi-quantitative polymerase chain reaction. PROJECTED ACCRUAL: Approximately 80-100 patients (20-25 with metastatic disease and 60-75 with non-metastatic disease) will be accrued for this study within 4-5 years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 2 Years

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed, newly diagnosed, primary intracranial embryonal central nervous system tumor * Medulloblastoma * Primitive neuroectodermal tumor * Medulloepithelioma * Ependymoblastoma * Neuroblastoma * Pineoblastoma * Atypical teratoid/rhabdoid tumor * Intracranial germ cell tumor * Choroid plexus carcinoma * M positive ependymoma * Potential enrollment on PBTC-001 therapeutic protocol PATIENT CHARACTERISTICS: Age: * Under 3 Performance status: * Not specified Life expectancy: * Not specified Hematopoietic: * Not specified Hepatic: * Not specified Renal: * Not specified PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Prior steroids allowed Radiotherapy: * No prior radiotherapy Surgery: * Not specified Other: * No concurrent investigational agents

Design outcomes

Primary

Measure	Time frame
Genes that are expressed in metastatic vs. non-metastatic tumors	Prior to therapy

Secondary

Measure	Time frame
Protein expression of genes found to be expressed	Prior to therapy

Countries

United States

Outcome results